ArticleOrphanet journal of rare diseases2023

Safety and tolerability of agalsidase beta infusions shorter than 90 min in patients with Fabry disease: post-hoc analysis of a Japanese post-marketing study.

Chae Sung Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.